ClinicalTrials.gg
RecruitingNCT03729180Updated Nov 16, 2026

The ImPreSS Trial: Pharmacogenomic Decision Making at Time of Surgery

An interventional study of Routine Elective Surgery- In patient or out patient elective surgery and Blood test for genetic testing in Surgery, sponsored by University of Chicago. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by University of Chicago · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Jan 2019; still recruiting 7 years 10 months later.
Updated Nov 16, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,900
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The study is enrolling adults who are scheduled for either inpatient or outpatient elective surgical procedures at The University of Chicago.

At pre-operative visits, patients will be consented and a blood sample will be obtained for preemptive genotyping across a panel of actionable germline variants predicting drug response or toxicity risk.

Genotyping results will be delivered to participating providers as patient-specific drug-gene clinical decision support summaries using a secured Web portal, the Genomic Prescribing System (GPS).

Participating anesthesiologists and critical care and pain management physicians and associated providers from the Department of Anesthesia and Critical Care at the University of Chicago will be invited to receive results for their participating patients.

There will be an initial 6- month "run-in" period of the study comprised of approximately 100 enrolled adults in which all patients will have pharmacogenomic results made available to providers. The run-in period will allow for process refinement and GPS delivery to be examined and optimized prior to the randomized phase

After the initial run-in period, patients will be randomized to one of two arms - in the pharmacogenomic arm, providers will have access to GPS and pharmacogenomic information, whereas in the control arm, providers will not have access to GPS and patient-specific pharmacogenomic information (current standard of care).

02

Conditions studied

  • Surgery
03

In context

Lead sponsor

University of Chicago is the lead sponsor of 926 studies on the registry; 187 are open to participants now.

Of its 103 completed or terminated interventional studies of FDA-regulated products, 72 (70%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients who have planned elective surgical procedures at the University of Chicago
  • Must be aged 18 years or older

Exclusion criteria

Exclusion Criteria:

  • Patients who have undergone, or are being actively considered for, liver or kidney transplantation
  • Patients with known active or prior leukemia.
  • Inability to understand and give to participate.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
1,900 participants (estimated)

Study arms

  • Other
    Pain Cohort

    Patients with a post-operative pain consult will be included in a pain sub-analysis to assess pain scores, pain therapy administration, and rate of opioid-induced adverse events.

    Procedure: Routine Elective Surgery- In patient or out patient elective surgery · Diagnostic Test: Blood test for genetic testing · Other: Drug-genetic Profile

  • Experimental
    Pharmacogenomic (PGx) Arm [Randomization Arm 1]

    All patients will undergo preemptive genotyping prior to their surgical procedure, and all patients will have pharmacogenomic results made available to providers.

    Procedure: Routine Elective Surgery- In patient or out patient elective surgery · Diagnostic Test: Blood test for genetic testing · Other: Drug-genetic Profile

  • Other
    Control Arm [Randomization Arm 2]

    All patients will undergo preemptive genotyping prior to their surgical procedure. Pharmacogenomic test results will not be made available to providers (standard of care). Genotyping results will be released to study providers (and patients) at the 6-month unblinding timepoint for patients in the control group.

    Procedure: Routine Elective Surgery- In patient or out patient elective surgery · Diagnostic Test: Blood test for genetic testing

Interventions

  • ProcedureRoutine Elective Surgery- In patient or out patient elective surgery

    Participants will be undergoing routine planned surgeries.

  • Diagnostic testBlood test for genetic testing

    Blood test to determine differences in genes which may affect how certain medications affect the participant. All patients will consent to collection of a blood sample for preemptive genotyping across a panel of actionable germline variants predicting drug response or toxicity risk.

  • OtherDrug-genetic Profile

    Profile describing drugs that may be high-risk, those that should be used with caution, or drugs that are favorable to use based on the participants genes.

06

What researchers measure

Primary outcomes

  1. The frequency of Genomic Prescribing System (GPS) use by anesthesiologists and pain medicine physicians and associated providers during the perioperative period.

    To explore the feasibility and utility of implementing broad preemptive pharmacogenomic testing in the perioperative setting by determining the frequency of Genomic Prescribing System (GPS) use by anesthesiologists and pain medicine physicians and associated providers during the perioperative period.

    Time frame: 5 years

  2. Rate of use of high-risk drugs in perioperative setting

    To determine the rate of use high-risk drugs (red or yellow pharmacogenomic risk) in the group of patients for whom pharmacogenomic results are available compared to their rate of use (without provider knowledge of pharmacogenomic risk designation) in the control arm.

    Time frame: 5 years

Secondary outcomes

  1. Rate of use of favorable drugs in perioperative setting

    To determine the occurrence of specific pharmacogenomically-informed adverse drug events in both arms.

    Time frame: 5 years

  2. Occurrence of specific pharmacogenomically-informed adverse drug events

    To determine the occurrence of specific pharmacogenomically-informed adverse drug events in both arms.

    Time frame: 5 years

  3. Pharmacogenomic result availability on pain management services in both arms using a research database for each patient

    To explore the effects of pharmacogenomic result availability on pain management services in both arms.

    Time frame: 5 years

  4. Comparison of pain scores on a 10 point scale

    To compare pain scores between both arms.

    Time frame: 5 years

  5. Anesthesia and critical care providers knowledge and perceptions of prescribing decisions using a information provided in research database

    To determine anesthesia and critical care providers' knowledge and perceptions of prescribing decisions in order to develop better genomic delivery systems in the future

    Time frame: 5 years

  6. Differences in patient reported satisfaction using research database

    To determine whether differences in patient-reported satisfaction and adherence likelihood are observable for patients whose providers access and use pharmacogenomic information.

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Truong TM, Apfelbaum JL, Danahey K, Schierer E, Ludwig J, George D, House L, Karrison T, Shahul S, Anitescu M, Choksi A, Hartman S, Knoebel RW, van Wijk XMR, Yeo KJ, Meltzer DO, Ratain MJ, O'Donnell PH. Pilot Findings of Pharmacogenomics in Perioperative Care: Initial Results From the First Phase of the ImPreSS Trial. Anesth Analg. 2022 Nov 1;135(5):929-940. doi: 10.1213/ANE.0000000000005951. Epub 2022 Feb 25. PubMed 35213469 ↗
  • Truong TM, Apfelbaum JL, Schierer E, Danahey K, Borden BA, Karrison T, Shahul S, Anitescu M, Gerlach R, Knoebel RW, Meltzer DO, Ratain MJ, O'Donnell PH. Anesthesia providers as stakeholders to adoption of pharmacogenomic information in perioperative care. Pharmacogenet Genomics. 2022 Apr 1;32(3):79-86. doi: 10.1097/FPC.0000000000000455. PubMed 34570085 ↗
  • Truong TM, Apfelbaum J, Shahul S, Anitescu M, Danahey K, Knoebel RW, Liebovitz D, Karrison T, van Wijk XMR, Yeo KJ, Meltzer D, Ratain MJ, O'Donnell PH. The ImPreSS Trial: Implementation of Point-of-Care Pharmacogenomic Decision Support in Perioperative Care. Clin Pharmacol Ther. 2019 Dec;106(6):1179-1183. doi: 10.1002/cpt.1567. Epub 2019 Aug 21. No abstract available. PubMed 31433489 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jan 2019 (actual). Primary completion is estimated for Aug 2028, 115 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Aug 2027 → Aug 2028 and completion Aug 2027 → Aug 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2018
First posted
Nov 2, 2018
StartActual
Jan 22, 2019
Primary completionEst.
Aug 22, 2028was Aug 2027
CompletionEst.
Aug 22, 2028was Aug 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 22, 2027→Aug 22, 2028
Nov 16, 2026
Study completion
Aug 22, 2027→Aug 22, 2028
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Primary completion Aug 22, 2027→Aug 22, 2028
    Study completion Aug 22, 2027→Aug 22, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03729180
Responsible party
Sponsor
First posted
Nov 2, 2018
Start date
Jan 22, 2019
Primary completion
Aug 22, 2028 (estimated)
Completion
Aug 22, 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Cancer Clinical Trials Office
Contact
cancerclinicaltrials@bsd.uchicago.edu
1-855-702-8222
Peter O'Donnell
principal investigator · University of Chicago

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion